Introduction {#s1}
============

*Neisseria meningitidis* is an important cause of rapidly progressive septicaemia and meningitis in children and young adults ([@bib31]); case fatality rates for bacteraemic disease remain at around 10%, and a significant proportion of survivors are left with long-term sequelae ([@bib32]). For most individuals, however, this human-specific bacterium is primarily a non-pathogenic commensal of the nasopharynx, and up to 40% of the population are healthy carriers ([@bib3]). The mechanisms underlying human genetic influences that govern the development of invasive disease or asymptomatic carriage are incompletely understood. It is known, however, that complement activation is critical for protection against disease, evident from the susceptibility of individuals with genetic deficiency of either the alternative complement pathway (AP) or terminal pathway activation, and among those receiving therapy that prevents terminal pathway activation ([@bib26]; [@bib21]). Amongst several strategies that promote complement evasion*, N. meningitidis* recruits the human negative complement regulator, complement factor H (CFH), to its surface by expressing factor H binding protein (fHbp) ([@bib25], [@bib27]; [@bib17]). fHbp can be divided into three variant groups (V1, V2, and V3), which have \>85% sequence identity within the groups but only 60--70% similarity between groups ([@bib19]; [@bib2]). fHbps from all variant groups bind CFH with a *K*~*D*~ in the low nanomolar range ([@bib12]). Therefore, it is significant that the only single nucleotide polymorphisms (SNPs) associated with meningococcal disease in a recent genome-wide association study (GWAS) were those among the *CFH--CFHR* locus. These included SNPs within *CFH* and the downstream gene, *CFHR3* ([@bib4]). While CFH has been extensively studied (reviewed in [@bib18]), the role of the serum protein CFHR3 has not been unambiguously established (reviewed in [@bib15]).

Results and discussion {#s2}
======================

We recently demonstrated that three of the five CFHR proteins (i.e., CFHR1, 2, and 5) compete with CFH for binding to C3b on heterologous erythrocytes, thereby promoting complement activation ([@bib8]). Given the association of CFHR3 with meningococcal disease ([@bib4]), we investigated whether this protein and CFHR4 also act as CFH antagonists in this assay. We generated full-length CFHR3 and CFHR4B (which both consist of five complement control protein \[CCP\] domains, [Figure 1A](#fig1){ref-type="fig"}) and truncated versions of these proteins, and we examined their ability to influence complement activation by the AP, which is regulated by CFH ([@bib18]). Erythrocyte haemolysis assays demonstrate that CFHR3 and CFHR4B are also CFH antagonists on this surface, with their two C-terminal domains enabling them to compete with CFH for binding sites on cell complement fragments such as C3b ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). Additional cell-surface recognition sites within other domains ([Figure 1A](#fig1){ref-type="fig"}) increase the activity of the full-length CFHR3 and CFHR4B as competitive antagonists of CFH ([Figure 1B](#fig1){ref-type="fig"}) at physiologically relevant concentrations of ∼1 μM ([@bib6]; [@bib10]).10.7554/eLife.04008.003Figure 1.CFHR3 binds *N. meningitidis* fHbp at the same site as CFH and promotes complement activation.(**A**) Complement control protein (CCP) domains of CFH, CFHR3, and CFHR4 are shown with the sequence identity to CFH and between the CFHRs indicated. Key functional regions of CFH are noted. (**B**) CFH-dependent alternative pathway (AP) haemolytic assay ([@bib8]). Using a CFH dose that reduced lysis of guinea pig erythrocytes to 50%, the addition of increasing concentrations of either full-length or C-terminal fragments of CFHR3 or CFHR4 resulted in a dose-dependent increase in lysis. The two N-terminal CCP domains from CFHR3 had no effect (not shown). (**C**) Surface plasmon resonance (SPR) was used to investigate interactions of CFHRs with fHbp. Full-length and fragments of CFH and CFHRs were injected (black bar) over surface bound fHbp~3.28~. Only CFHR3~12~, full-length CFHR3, or CFH~67~ bind to fHbp. (**D**) Dissociation constants (K~D~) measured by SPR (CFHR3~12~) or microscale thermophoresis (CFHR3) indicated the fHbp binding site is within the two N-terminal domains of CFHR3. (**E**) SPR with 200 nM protein flowing over V3.28 fHbp demonstrates that the single point mutation E255A, which ablates CFH binding, also ablates CFHR~12~ binding.**DOI:** [http://dx.doi.org/10.7554/eLife.04008.003](10.7554/eLife.04008.003)10.7554/eLife.04008.004Figure 1---figure supplement 1.Increased haemolysis on addition of CFHR3 is dependent on presence of CFH and interaction of CFHR3 full length and N-terminal fragment with V3.28 fHbp.(**A**) Haemolysis of guinea pig erythrocytes by 5% CFH depleted serum (CompTech, TX, USA) was measured upon addition of a range of CFHR3 concentrations (4 nM--2 μM) in Mg-EGTA to ensure activation by the alternative pathway (AP) alone. Haemolysis is presented as a percentage of maximal lysis by H~2~O. No significant differences in haemolysis were observed under any of the conditions. (**B**) Supplementing the CFH deficient serum (CompTech, TX, USA) with 100 nM CFH reduced lysis to ∼20%. In this CFH-supplemented experiment addition of 2 mM CFHR3 led to a significant (p = 0.003, two-tailed, unpaired *t* test) increase in haemolysis as seen with the naturally CFH sufficient serum in [Figure 1](#fig1){ref-type="fig"}. (**C**) Full-length CFHR3 interacts strongly with the carboxymethyldextran matrix used to immobilise proteins in SPR, therefore, microscale thermophoeresis ([@bib28]), a solution technique, was used to measure the affinity for V3.28 fHbp. The data plotted are mean ± SE for nine repeats, which were simultaneously fit to derive the K~D~ and error estimate shown. (**D**) SPR was used to measure the K~D~ of the interaction with V3.28 fHbp (see 'Materials and methods'). Data from a single experiment are shown whilst the K~D~ and fit statistics are mean ± SD for four independent repeats.**DOI:** [http://dx.doi.org/10.7554/eLife.04008.004](10.7554/eLife.04008.004)

*N. meningitidis* fHbp recruits CFH by high-affinity interactions primarily with domain 6 of CFH (CFH~6~) with some limited contact to CFH~7~ ([@bib27]). Since the first domains of the CFHRs share between 40% to 90% identity with CFH~6~ ([Figure 1A](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}), we next investigated whether fHbp also bound the CFHRs. Our findings ([Figure 1C](#fig1){ref-type="fig"}) demonstrate that CFHR3 binds fHbp with a *K*~*D*~ of ∼3 nM, similar to affinities for CFH ([@bib27]; [@bib12]); no significant binding was detected for the other CFHRs with fHbp. Of note, the first two domains of CFHR3 (CFHR3~12~; domain 1 shares 91% identity with CFH~6~, [Figure 1A](#fig1){ref-type="fig"}) and the full-length protein bind fHbp with similar affinities ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C,D](#fig1s1){ref-type="fig"}). Furthermore, a point mutation within fHbp (E255A) that reduces binding to CFH by more than three orders of magnitude ([@bib12]) similarly reduces CFHR3 binding ([Figure 1E](#fig1){ref-type="fig"}). The nature of the CFH and CFHR3 interactions with fHbp are therefore similar, with these complement factors occupying overlapping sites on fHbp, which is consistent with the high degree of conservation of their fHbp binding sites ([Figure 2](#fig2){ref-type="fig"}).10.7554/eLife.04008.005Figure 2.Amino acid differences between CFHR3 and CFH in the fHbp binding site.(**A**) Sequence alignment between CFHR3~12~ and CFH~67~. Differences are highlighted in red text, the two differences within the fHbp binding site are highlighted in yellow and residues contacting fHbp in the CFH-fHbpV3 structure (PDB ID 4AYM \[[@bib12]\]), chains A and D are indicated by an asterisk below the CFH sequence. (**B**) CFH~67~ is shown as a grey surface with residues that differ in CFHR3 highlighted in red; fHbp is shown as a green ribbon. (**C**) Rotated 90° around x compared to the view in **B**. (**D**) Looking down onto the fHbp binding site on CFH the two, conservative, sequence differences between the CFH~67~ and CFHR3~12~ found in the binding site are indicated in red on the grey surface.**DOI:** [http://dx.doi.org/10.7554/eLife.04008.005](10.7554/eLife.04008.005)

Next we investigated whether CFHR3 binds to the surface of *N. meningitidis*. We generated a CFHR3-specific monoclonal antibody (mAb) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), designated HSL1. By flow cytometry we demonstrated that serum CFHR3 bound *N. meningitidis* M1239 (which expresses V3.28 fHbp) in a fHbp-dependent manner. No binding was detected following incubation of bacteria in sera from an individual homozygous for an allele in which there is combined deletion of the *CFHR1* and *CFHR3* genes (Δ*CFHR3/1*) (Δ*CFHR3/1*, [Figure 3A,B,C](#fig3){ref-type="fig"}). We therefore tested the functional consequences of CFHR3 binding by comparing the effect of adding full length or domains of CFHR3 to *N. meningitidis* prior to incubation in normal human serum (NHS). Addition of full-length CFHR3 or CFHR3~12~, which contains the fHbp binding site ([Figure 1C](#fig1){ref-type="fig"}) but has no CFH antagonist activity ([Figure 1B](#fig1){ref-type="fig"}), resulted in significantly reduced bacterial survival (CFHR3 51%; CFHR3~12~ 70%; no protein or CFHR3~45~ 83%, [Figure 3D](#fig3){ref-type="fig"}); in contrast, CFHR3 had no detectable effect in the presence of heat-inactivated NHS (which lacks complement activity, [Figure 3D](#fig3){ref-type="fig"}). Full-length CFHR3 has a more marked effect on bacterial survival than CFHR3~12~, consistent with the ability of the full-length CHHR3 to bind to C3b deposited on the bacterial surface (via CFHR3~45~) as well as competing with CFH for fHbp (via CFHR3~12~). As CFHR3~45~ does not bind fHbp ([Figure 1C](#fig1){ref-type="fig"}), its CFH antagonist activity is not effectively localized to the meningococcal surface, providing an explanation for why these domains have no effect on bacterial survival ([Figure 3D](#fig3){ref-type="fig"}). Similarly, addition of CFHR3 has no effect on serum survival of bacteria that do not express any CFH-binding protein ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}, *N. meningitidis* strain lacking fHbp expression; [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}, Escherichia *coli* strain with no expression of any CFH-binding protein).10.7554/eLife.04008.006Figure 3.*N. meningitidis* binds CFHR3 on its surface in an fHbp-dependent manner promoting complement-mediated lysis.(**A**--**C**) Flow cytometry of *N. meningitidis* demonstrates that CFHR3 binds to fHbp on the bacterial surface. (**D**) Sensitivity of *N. meningitidis* strain M1239 to complement-mediated cell lysis after pre-incubation with 1 µM CFHR3, CFHR3~12~, CFHR3~45~, or no protein. Faded symbols are bacteria incubated in identical conditions except using heat-inactivated NHS instead of NHS. Data presented as percentage survival relative to bacteria incubated in heat-inactivated NHS without additional CFHR3. Line shows the mean of three independent biological experiments, each with three technical replicates; individual results indicated. Significance was calculated using a two-tailed unpaired *t* test comparing with values obtained with no additional protein: \*\*\*\*p \< 0.0001; \*p \< 0.05; ns p \> 0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.04008.006](10.7554/eLife.04008.006)10.7554/eLife.04008.007Figure 3---figure supplement 1.Characterisation of the novel anti-CFHR3 antibody HSL1.(**A**) Western blotting of recombinant CFHR3 and sera from individuals sufficient or deficient in *CFHR3* demonstrates that HSL1 is specific for CFHR3. (**B**) For screening of mAbs, ELISA plates (F96 maxisorp, Nunc) were coated with C-terminal pair of CCP domains of CFH and the CFHRs (5 µg/ml, 50 µl per well) overnight at room temperature before blocking with 2% skimmed milk in PBS 0.05% Tween 20. Plates were incubated with neat hybridoma culture supernatant and binding was detected with goat anti-mouse HRP (1 in 5000, Dako) followed by ELISA substrate and stop solution (Roche).**DOI:** [http://dx.doi.org/10.7554/eLife.04008.007](10.7554/eLife.04008.007)10.7554/eLife.04008.008Figure 3---figure supplement 2.The effect of CFHR312 on bacterial survival is dose and fHbp dependent.(**A**) Survival of *N. meningitidis* M1239 (filled circles) and M1239Δfhbp (unfilled circles) in the presence of NHS following pre-incubation in different concentrations of CFHR3~12~ (indicated). Data presented as percent survival relative to bacteria incubated in the absence of serum and CFHR3~12~. Error bars are ±SEM of three independent experiments. (**B**) Serum survival of *E. coli* DH5α (which does not express a CFH-binding surface protein) is not altered by pre-incubation with CFHR3. Data presented as percent survival relative to bacteria incubated in the absence of serum and CFHR3. Error bars are ±SEM of three separate experiments repeated four times. Significance was calculated using a standard one-way ANOVA with Tukey\'s multiple comparison test (n.s., not significant; \*\*\*\*p \< 0.0001).**DOI:** [http://dx.doi.org/10.7554/eLife.04008.008](10.7554/eLife.04008.008)

The finding that CFHR3 binding impairs bacterial survival in NHS led us to consider whether fHbp can distinguish between the limited sequence differences between CFH and CFHR3 to generate specificity for CFH. We previously identified a series of alanine substitutions in fHbp that significantly reduce or ablate CFH binding ([@bib12]). Therefore, we measured the contribution of fHbp residues to interactions with CFHR3 to determine whether any amino acid changes altered the specificity of fHbp for the two complement factors ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---source data 1](#SD1-data){ref-type="supplementary-material"}). The results demonstrate that the majority of mutations that impair CFH binding ([@bib12]) also significantly reduce CFHR3 binding, so do not alter specificity for CFH; point mutations at only a few sites led to modest alterations in specificity at levels that are unlikely to be physiologically relevant given the relative affinities for CFHR3/CFH and their abundance in serum (CFHR3 1--1.6 μM \[[@bib6]; [@bib10]\]; CFH 1--4 μM \[[@bib9]\]). Interestingly the V1 fHbp used as the background for the mutations (V1.1) did reveal a degree of specificity for CFH over CFHR3 (in the order of ∼20-fold) in contrast to V2 and V3 fHbps, suggesting that certain fHbps can discriminate between CFH and CFHR3.10.7554/eLife.04008.009Figure 4.Key residues in fHbp that mediate binding to CFHR3.(**A**) SPR was used to determine *K*~*D*~s for both CFH~67~ and CFHR3~12~ binding to a panel of fHbps bearing alanine substitutions within the CFH~67~ binding site. ∼50 mutations were screened in each of three fHbps (V1.1, 2.21 and 3.28 \[[@bib12]\]). Mutations altered *K*~*D*~s for both CFH~67~ and CFHR3~12~ but some mutations led to some specificity for binding one or the other protein (see full data in Extended Data File 1). (**B**) *K*~*D*~s were determined for a panel of fHbps from disease causing *N. meningitidis*. V1 fHbps have some ability to preferentially bind CFH~67~ vs CFHR3~12~, whilst V2 and V3 fHbps were less able to distinguish the molecules (full data in Extended Data File 2). (**C**) AP-mediated bacterial killing of isogenic strains expressing different fHbps in the presence of CFHR3. Data are coloured as in panel (**B)** and bacterial survival in serum is increased in the strain expressing the fHbp~V1.1~ (that has the maximal specificity for CFH vs CFHR3).**DOI:** [http://dx.doi.org/10.7554/eLife.04008.009](10.7554/eLife.04008.009)10.7554/eLife.04008.010Figure 4---source data 1.Excel spreadsheet with full details of K~D~s for CFH and CFHR3~12~ derived from 1:1 Langmuir fits of SPR data for alanine scanning mutants and natural variant fHbp sequences.**DOI:** [http://dx.doi.org/10.7554/eLife.04008.010](10.7554/eLife.04008.010)

To investigate this further, we measured binding of CFH and CFHR3 to 25 naturally occurring fHbps that are prevalent in disease isolates of *N. meningitidis* ([Figure 4B](#fig4){ref-type="fig"}, [Figure 4---source data 1](#SD1-data){ref-type="supplementary-material"}) ([@bib16]). This demonstrated that V2 and V3 fHbps displayed no selective affinity for CFH over CFHR3 (average selectivity being 1.8 ± 1.4 and 2.4 ± 1.0, respectively). In contrast, V1 fHbps had lower affinities for CFHR3 compared to CFH (average selectivity 8.9 ± 4.6-fold), with 12 of the 14 V1 fHbp variants binding CFH 5- to 20-fold more tightly than CFHR3. Modeling the effect on the occupancy of fHbp with CFH indicates that certain V1 fHbps will be bound by CFH in the physiological situation regardless of CFHR3 levels ([Figure 5](#fig5){ref-type="fig"}). To examine whether this has any functional consequence, we examined complement AP killing of isogenic strains expressing fHbp sequences with different abilities to discriminate between CFH and CFHR3 ([Figure 4C](#fig4){ref-type="fig"}); AP killing was assessed to exclude any confounding influence of antibodies in sera preferentially recognizing different fHbps. Bacteria expressing V3.28 fHbp, which has identical affinities for CFH and CFHR3, were the most sensitive to AP killing, while the strain expressing the V1.1 fHbp sequence (which has ∼20-fold tighter binding to CFH than CFHR3) was the least sensitive; bacteria with fHbps with intermediate CFH specificity displayed intermediate levels of protection. This suggests that, even though the most specific fHbps bind CFHR3 with a *K*~*D*~ significantly below the physiological concentration ([Figure 4---source data 1](#SD1-data){ref-type="supplementary-material"}), the ability of fHbp to favour CFH binding promotes bacterial survival and offers a potential explanation for the prevalence of strains expressing V1 fHbp causing invasive disease ([@bib16]).10.7554/eLife.04008.011Figure 5.Modelling the occupancy of bacterial cell surface fHbp assuming different levels of specificity for CFH over CFHR3.Each molecule of fHbp on the bacterial surface can bind with one molecule of CFHR3 or one molecule of CFH. Assuming that the number of molecules of either of these is significantly greater than the number of molecules of fHbp then the percentage of bacterial surface fHbp molecules binding CFH at equilibrium will be determined by: the relative amounts of both present in the individual; and the affinities of that fHbp sequence for CFH vs CFHR3 (essentially a model of competitive antagonism, see equation below). Natural fHbp sequences are relatively constant in their K~D~ for CFH (K~D~ ∼3 nM \[[@bib12]\] and this work), therefore we modelled the effect of the K~D~ for CFHR3 varying between 3 nM and 300 nM against this constant K~D~ for CFH under two conditions. In red we assume that both CFH and CFHR3 are present in serum at 1.5 μM, whilst in blue we model the effect if the concentration of CFH is twice that of CFHR3 (i.e., 3 μM vs 1.5 μM). This range of relative concentrations covers those generally reported for CFH and CFHR3 (except in the case of *ΔCFHR3/1* individuals where the concentration of CFHR3 will be zero and 100% of the fHbp will bind CFH). The grey shaded areas indicate the regions of the x axis into which the families of natural variant fHbp sequences studied in [Figure 3](#fig3){ref-type="fig"} fall. The equation used to generate these curves is:$$Occupancy\, CFH = \frac{\frac{\left\lbrack CFH \right\rbrack}{K_{D}\left( CFH \right)}}{\frac{\left\lbrack CFH \right\rbrack}{K_{D}\left( CFH \right)} + \frac{\left\lbrack CFHR3 \right\rbrack}{K_{D}\left( CFHR3 \right)} + 1} \ast 100.$$**DOI:** [http://dx.doi.org/10.7554/eLife.04008.011](10.7554/eLife.04008.011)

To define the basis for the effect of CFHR3 on bacterial survival, we next examined the impact of CFHR3 on levels of CFH bound to the bacterial surface. *N. meningitidis* incubated in the Δ*CFHR3/1* sera acquire high levels of CFH on the bacterial surface ([Figure 6A,B,C](#fig6){ref-type="fig"}). However, addition of recombinant CFHR3 reduces the amount of bound CFH in a dose-dependent manner, demonstrating antagonism between CFH and CFHR3 for binding to the bacterial surface. When the amount of recombinant CFHR3 is added at approximately equimolar levels to those in NHS, the level of CFH bound on the bacterial surface is only half that seen in the CFHR3-deficient sera (1--1.6 μM \[[@bib6]\]).10.7554/eLife.04008.012Figure 6.Susceptibility to *N. meningitidis* will be altered by the circulating levels of CFH and CFHR3 that compete for binding to fHbp.(**A**--**C**) Flow cytometry demonstrates that addition of increasing amounts of CFHR3 (from 0 μM \[light blue\] to 1 μM \[black\]) to sera from a *Δ*CFHR3--1 individual leads to decreasing levels of CFH on the bacterial surface (**A** and **C**) and increasing levels of CFHR3 (**B** and **C**). (**D**) Model of how differing levels of CFHR3 and CFH in an individual combine to alter the amount of CFH hijacked to the bacterial surface, hence the level of complement-mediated bacterial killing and an individual\'s susceptibility to meningococcal disease.**DOI:** [http://dx.doi.org/10.7554/eLife.04008.012](10.7554/eLife.04008.012)

In summary, our work demonstrates that susceptibility to an important infectious disease is governed by the competition between two complement factors with opposing effects (CFH and CFHR3) for overlapping binding sites on a single pathogen molecule. Our data predict that the risk of developing meningococcal disease will be governed by the relative abundance of CFH and CFHR3 in individuals and the affinity of these molecules for the specific fHbp on the bacterial surface ([Figure 6D](#fig6){ref-type="fig"}). It is notable that the Δ*CFHR3/1* allele has a high prevalence in sub-Saharan Africa ([@bib11]) where there are high rates of epidemic disease. Our mechanism is consistent with this association, since this allele would enhance the interaction between CFH and fHbp and favour pathogen survival. This is particularly true as the *ΔCFHR3/1* deletion is associated with increased plasma CFH levels, most likely due to the loss of a regulatory locus ([@bib1]; [@bib33]). However, host polymorphisms in CFHR3 might have less impact on strains of bacteria that express fHbp that more selectively bind CFH. Therefore, susceptibility to meningococcal disease will be influenced by polymorphisms and copy number variation affecting two host complement factors and by the relative affinity of fHbp on an infecting strain for CFH and CFHR3. This illustrates why genetic association studies in infectious diseases are likely to be technically challenging since these will be influenced not only by sequence and structural variation within the host but also by genetic variation in pathogen.

Materials and methods {#s3}
=====================

Cloning and mutagenesis for protein expression {#s3-1}
----------------------------------------------

Sequences encoding CFHR1~45~, CFHR3~12~, CFHR3~45~ and CFHR4~45~ were amplified using primer pairs CFHR1-4-Forward(5′-GAAGGAGATATACCATGACGGGAAAATGTGGGCC-3′)/CFHR1-5-Reverse(5′-GGCCCACATTTTCCCGTCATGGTATATCTCCTTC-3′), CFHR3-1-Forward(5′-GATATACATATGAAACCTTGTGATTTTCCAGACATTAAAC-3′)/CFHR3-2-Reverse(5′-GGATCCTCGAGCTAACGGATGCATCTGGGAGTAG-3′), CFHR3-4-Forward(5′-GGCAGCCATATGTCAGAAAAGTGTGGGCCTCCTC-3′)/CFHR3-5-Reverse(5′- CGGATCCTCGAGTTATTCGCATCTGGGGTATTCCACTATC-3′) and CFHR3-4-Forward/CFHR4-5-Reverse(5′- CGGATCCTCGAGTTATTCGCATCTGGGGTATTCCACTATG-3′), respectively. The sequence encoding CFHR5~89~ was amplified using primer pair CFHR5-8-Forward(5′-CCACATATGGCATATTGTGGGCCCCCTCCATC-3′)/CFHR5-9-Reverse(5′-GGATCCTCGAGTCATTCACATATAGGATATTCAAATTTC-3′). Inserts were cloned between the NdeI and XhoI sites of a modified version of vector pET-15b (Novagen, Merck Millipore, Billerica, MA), which has the NcoI site replaced with an NdeI site.

A vector encoding FH~19--20~ was generated from that encoding CFHR1~45~ using site-directed mutagenesis with primers L183S-Forward(5′-GGACAGCCAAACAGAAGCTTTATTCGAGAACAGGTGAA-3′)/L183S-Reverse(5′-TTCACCTGTTCTCGAATAAAGCTTCTGTTTGGCTGTCC-3′) and A189V-Forward(5′-TTTGAGAACAGGTGAATCAGTTGAATTTGTGTGTAAACGGG-3′)/A189V-Reverse(5′- CCCGTTTACACACAAATTCAACTGATTCACCTGTTCTCAAA-3′).

The gene encoding full-length CFHR3 was amplified using primers encoding a histidine (His) tag (CFHR3-Forward 5′-ATTCGCGGCCGCCCCACCATGTTGTTACTAATCAAT-3′ and CFHR3-Reverse 5′-CACCATCACCATCACCATTAGCTCGAGGAA-3′) and cloned into a modified version of the pCAGGS plasmid ([@bib29]) bearing the CMV-EI enhancer, the chicken β-actin promoter, and intron 1 of the simian virus 40 poly(A) signal.

The gene encoding full-length CFHR4 was amplified using primer pair CFHR4-Forward(5′- GGACTGTCTAGAGACTCAGATCCCCATCCGCTCAAGCAGGCCACCATGTTGTTACTAATCAATGTCATTCTGACC-3′)/CFHR4-Reverse(5′ GTGTCGGGTCGACCCTTCGCATCTGGGGTATTCCAC-3′) prior to ligation into vector pEF-BOS ([@bib23]) between the XbaI and SalI sites giving a C-terminal hexahistidine tag.

Recombinant protein expression and purification {#s3-2}
-----------------------------------------------

Recombinant His-tagged fHbp was prepared from a selection of natural variant fHbps and alanine substitution mutants of fHbp V1, V2, and V3 as described previously ([@bib12]). All three variant types were represented within 27 natural fHbp variant sequences, numbered according to an allele ID code as detailed on the Neisseria Multi Locus Sequence Typing website (<http://pubmlst.org/neisseria/>) developed by Keith Jolley and sited at the University of Oxford ([@bib13]).

CFH~67~ was prepared as previously described ([@bib24]). CFH~19--20~, CFHR1~45~, CFHR3~45~, CFHR4~45~, and CFHR5~89~ were expressed in *E. coli* and refolded from inclusion bodies prior to size exclusion chromatography (Superdex S-75, GE Healthcare, Little Chalfont, UK, buffer 50 mM Tris pH 7.5, 150 mM NaCl) using the same method previously described for CFHR2~45~ ([@bib8]). CFHR1~12~ was expressed in *Kluyveromyces lactis* as previously described ([@bib8]). CFHR3~12~ was prepared in an identical manner to CFH~67~ with substitution of the final size exclusion chromatography step for purification using heparin affinity (Heparin FF column, GE Healthcare, buffer A: 50 mM Tris pH 7.5, 10 mM NaCl, buffer B: 50 mM Tris pH7.5, 1 M NaCl, elution gradient: 50% over 15 CV).

Recombinant His-tagged CFHR3 was expressed in HEK293 cells using Lipofectmine 2000 (Invitrogen) as per manufacturer\'s instructions. Recombinant His-tagged CFHR3 supernatant was purified by a single affinity chromatography step using a His-Trap HP (GE Healthcare) as per manufacturer\'s instructions. The bound protein was eluted with 500 mM Imidazole and then dialysed against 10 mM sodium phosphate pH7.8.

CFHR4 was expressed transiently in cell line HEK293S GntI^−/−^ from vector pEF-BOS. Transfection was performed using 293Fectin (Life Technologies, Carlsbad, CA) as per the manufacturers instructions. Cells were cultured in suspension using Freestyle 293 Expression medium (Life Technologies) at 37°C with 10% CO~2~ for 96 hr prior to harvesting the media. CFHR4 was purified from the media using a Ni-NTA column (Qiagen) as per the manufacturer's instructions. Purified protein was dialysed into phosphate buffered saline (PBS) prior to use.

Surface plasmon resonance {#s3-3}
-------------------------

All surface plasmon resonance measurements were made at 25°C using either a Biacore 3000 (GE Healthcare) or ProteOn XPR36 (BioRad, Hercules, CA) instrument with buffer HBS-EP (10 mM Hepes pH7.4, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant-P20). Proteins were immobilised via primary amine coupling with a mock activated--deactivated reference channel included on each. Measurement of the affinity between CFHR3~12~ and fHbp V3 was performed by immobilising approximately 1200 RU fHbp on the surface of a CM5 sensor chip (GE Healthcare). Dilution series of CFHR3~12~ ranging from 12.5 nM--0.2 nM were flowed over the surface at 40 µl/min using KINJECT with a contact time of 300 s and dissociation time of 1200 s. The surface was regenerated with 10 mM glycine pH 3.0 between each injection. Curves were mock subtracted and fit with a 1:1 Langmuir model using BiaEvaluation (GE Healthcare).

Analysis of binding of CFHRs and CFHR fragments to fHbp V3 was performed using a CM5 chip with approximately 1700 RU fHbp immobilised. 100 µl of each analyte at a minimum concentration of 200 nM was flowed over the surface at 20 µl/min using the KINJECT command with a dissociation time of 400 s. The surface was regenerated using 10 mM glycine pH 3.0 between injections. Curves were mock subtracted using BiaEvaluation.

Measurement of the large panel of fHbp mutants was performed by immobilization of the proteins on ProteOn GLM sensor chips (BioRad). Increasing concentrations of CFHR3~12~ or fH~67~ were injected over the flow channels at 60 µl/min for 240 s and allowed to dissociate for 1200 s. The surface was regenerated with 10 mM glycine pH 3.0 between each injection. Curves were mock subtracted and fit with a 1:1 Langmuir model using ProteOn manager software (BioRad).

Microscale thermophoresis {#s3-4}
-------------------------

fHbp V3 was labelled using the RED-NHS labelling kit (NanoTemper Technologies, Munich, Germany) as per the manufacturer's instructions. Dilution series of CFHR3~12~ in the range of 740 nM--23 pM were set up using HBS-EP. Each sample also contained 4 nM labelled fHbp. Thermophoresis was measured using a Monolith NT.115 instrument (NanoTemper Technologies) at 22°C utilising hydrophilic treated capillaries (NanoTemper Technologies), 80% LED power and 60% LED power. All data were measured in triplicate across three independent dilution series. Data were analysed using the signal from Thermophoresis + T-Jump (NT Analysis software version 1.5.41, NanoTemper Technologies).

Haemolytic assays {#s3-5}
-----------------

The effect of CFHR3, CFHR3~12~, CFHR3~45~, CFHR4, and CFHR4~45~ upon AP activation was assessed using haemolytic assays that were performed in an identical manner to that described in [@bib8]. All measurements were performed in triplicate and are presented as haemolysis relative to the level of lysis without addition of CFHR proteins (0%) and 100% lysis by H~2~O. Haemolytic assays with CFH-deficient serum (CompTech, Tyler, TX) were performed with 5% serum.

Bacterial strains and growth {#s3-6}
----------------------------

*N. meningitidis* was grown on brain heart infusion (BHI, Oxoid) agar supplemented with 5% Levinthal\'s base (500 ml defibrinated horse blood autoclaved with 1 l BHI) overnight at 37°C in the presence of 5% CO~2~ ([@bib16]; [@bib14]). M1239Δ*fhbp* was constructed as previously ([@bib14]) and isogenic strains were constructed by complementing the strains with fHbp V1.P1, V1.P14, V2.P22, or V3.P28 amplified using primers listed in [Table 1](#tbl1){ref-type="table"}. Polymerase chain reaction products were ligated into pGCC4 ([@bib22]). Transformation of *N. meningitidis* strain M1239Δ*fhbp* was performed as described previously ([@bib5]).10.7554/eLife.04008.013Table 1.Primers used to generate bacterial strains**DOI:** [http://dx.doi.org/10.7554/eLife.04008.013](10.7554/eLife.04008.013)Primer nameStrain amplifiedRefPrimer Sequence (restriction site underlined)pgcc4V1.1 FH44/76([@bib14])CGG[TTAATTAA]{.ul}GGAGTAATTTTTGTGAATCGAACTGCCTTCTGCTpgcc4V1.1 RH44/76([@bib14])CGG[TTAATTAA]{.ul}TTATTGCTTGGCGGCpgcc4V1.14 FNZ98/254CGG[TTAATTAA]{.ul}GGAGTAATTTTTGTGAACCGAACTGCCpgcc4V1.14 RNZ98/254CGG[TTAATTAA]{.ul}TTATTGCTTGGCGGCAAGACpgcc4V2.22FFAM18CGG[TTAATTAA]{.ul}GGAGTAATTTTTGTGAACCGAACTGCCTTCTGCTpgcc4V2.22RFAM18CGG[TTAATTAA]{.ul}CTACTGTTTGCCGGCGATGCpgcc4V3.28 FM1239CGG[TTAATTAA]{.ul}GGAGTAATTTTTGTGAATCGAACTGCCTTCTGCTpgcc4V3.28 RM1239CGG[TTAATTAA]{.ul}CTACTGTTTGCCGGCGATGC

Serum survival assay {#s3-7}
--------------------

NHS were obtained by collecting whole venous blood and allowing it to coagulate at room temperature for 60 min before centrifuging at 3000×*g* for 20 min at 4°C. Sera were heat inactivated at 56°C for 30 min prior to use. *N. meningitidis* was grown overnight on BHI agar, re-suspended in PBS then diluted to 1 × 10^5^ CFU/ml in DMEM (Sigma). A total of 1 × 10^4^ CFU of bacteria were pre-incubated with 1 µM CFHR3, 1 µM CFHR3 domains or PBS for 10 min prior to incubation with 5% human sera or 5% heat inactivated sera for 30 min at 37°C in the presence of CO~2~. Bacterial survival was determined by plating onto BHI agar. Relative survival was calculated from samples containing no CFHR3 and incubated with heat-inactivated sera and expressed as percentage survival.

For the AP assays, bacteria were grown on BHI agar supplemented with 1 mM IPTG. Other complement pathways were inhibited by the addition of 5 mM MgCl~2~/10 mM EGTA, and bacteria were incubated in 25% sera as above. Statistical significance was tested using the one-way ANOVA multiple comparisons as implemented in GraphPad Prism v.6.0 (GraphPad Software Inc.) to compare means ±S.E.M. using a p \< 0.01 cutoff for significance.

Monoclonal antibody production {#s3-8}
------------------------------

Recombinant CFHR3~45~ conjugated to KLH (Imject, Pierce) was used as an antigen. Female BALB/c mice were immunised with 100 μg of recombinant protein emulsified in TitreMax Gold (Sigma, UK) subcutaneously on day 1, then with 100 μg of CFHR3~45~ in PBS intraperitoneally (IP) on days 21 and 42. A booster of 200 μg of recombinant protein in PBS was given IP 3 days prior to cell fusion on day 63. NS0 myeloma cells were grown in RPMI 1640 (Lonza, UK) supplemented with 10% foetal bovine serum (FBS, Sigma, UK), 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 μg/ml) ([@bib7]). Splenectomy was performed on day 66, and splenocytes fused to NS0 myeloma in polyethylene glycol (PEG 1500, Roche, UK) ([@bib20]). Fused cells were then plated into 24-well plates in RPMI 1640 containing 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 μg/ml), and 1% Ultroser G (Pal France). After 24 hr, 2% hypoxanthine adminopterin thymidine (HAT, Life technologies) was added to the wells. Hybridoma clone supernatants were screened by ELISA against recombinant CFHR3~45~. Positive clones were re-plated and grown for a further 5 days before screening again by ELISA against the CFHR3~45~ and all five CFHR proteins. Positive hybridoma cells were sub-cultured into 96-well plates at a concentration of 1 cell per well in RPMI 1640 containing 10% FBS, 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 μg/ml), Ultroser G (1%), and BM Condimed H1 (1%, Roche, UK). After 5 days, wells containing single colonies were screened as before.

Flow cytometry {#s3-9}
--------------

Bacteria (1 × 10^9^ CFU/ml) were fixed in 1 ml of 3% formaldehyde for 2 hr then washed with PBS. To evaluate CFHR3 binding, 5 × 10^7^ CFU/ml were re-suspended in 10 μl of NHS or 10 µl of sera from an individual with *ΔCFHR3/1* for 30 min at room temperature. After two washes in 0.05% BSA/PBS, binding was detected following incubation with the anti-CFHR3 mAb (HSL1 this study) for 30 min at 4°C in 50 μl of PBS. Cells were washed twice in 0.05% BSA, then resuspended in 50 μl of goat anti-mouse IgG-Alexa Fluor 647 conjugate (1 in 1000 dilution in PBS; Molecular Probes, Life Technologies) and incubated for 30 min at 4°C. Samples were run on a FACSCalibur (BD Biosciences), and at least 10^4^ events recorded before results were analysed by calculating the geometric mean FL-4 in FlowJo vX software (Tree Star).

To evaluate the influence of CFHR3 on CFH binding to bacteria, 5 × 10^7^ CFU/ml of *N. meningitidis* M1239 were incubated in 10 µl of *ΔCFHR3/1* sera and twofold dilutions of recombinant full-length CFHR3 (from 1 µM) for 30 min at room temperature. CFHR3 binding was detected with the anti-CFHR3 mAb (HSL1 this study) or an anti-human CFH mAb (MRC OX24, 0.1 μg/ml) ([@bib30]), followed by incubating with goat anti-mouse IgG-Alexa Fluor 647 conjugate (1 in 1000 dilution in PBS; Molecular Probes, Life Technologies) and analysed by flow cytometry. At least 10^4^ events were recorded before results were analysed by calculating the geometric mean FL-4 in FlowJo vX software (Tree Star). Maximum fluorescence for CFHR3 was normalised to the addition of 1 µM exogenous CFHR3, whereas the maximum fluorescence for CFH was normalised without the addition of exogenous CFHR3. Statistical significance was tested using the one-way ANOVA multiple comparisons as implemented in GraphPad Prism v.6.0 (GraphPad Software Inc.) to compare means ±S.E.M. using a p \< 0.01 cutoff for significance.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Competition between antagonistic complement factors for a single protein on *N. meningitidis* rules disease susceptibility" for consideration at *eLife*. Your article has been favorably evaluated by Tadatsugu Taniguchi (Senior editor) and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before reaching the decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

This interesting and clinically relevant study provides data that allow a plausible explanation of human variability in outcomes of *Neisseria meningitidis* infection by defining both bacterial and host components that can vary to determine whether complement-mediated killing occurs within human serum. Previously, it is known that fHbp, a surface exposed lipoprotein from *N. meningitidis*, can bind to complement factor H (CFH), playing an important role of evasion of complement-mediated killing of the bacteria. Because of this, study of fHbp binding to CFH has important implications in vaccine design and improvement. In this work, the authors pursue a result from a genome-wide association study (GWAS) study of *N. meningitidis* that implicates human variability in CFHR3 as associated with host susceptibility. They demonstrate that CFHR3 could also bind to fHbp with a similar affinity as CFH and went further to show that the binding surface on fHbp by CFH and CFHR3 completely overlaps. They then demonstrate convincingly that CFHR3 promotes complement activation by competing with CFH on the bacterial surface. Finally, they further propose a model that the relative levels of two complement and related proteins (CFH and CFHR3) in the circulation system is a critical factor for determining the host susceptibility to meningococcal disease. In general, the study is very clearly written and provides an exciting and generally interesting observation. The concept proposed is novel and highly interesting given that there are five CFHR proteins that are often involved in binding to surface proteins of various bacterial pathogens. The paper is potentially suitable for *eLife* after addressing the following points.

1\) As a rationale for the study and also a clinically relevant conclusion, the authors point to a recent GWAS study showing linkage disequilibrium to a specific single nucleotide polymorphism (SNP) and hence indicating the possibility that the linkage could be a result of deletion of CFHR3/CFHR1. In reading the Nature Genetics report, though, it does not appear that the CFHR3/CFHR1 deletion itself is linked to disease risk, but the association is rather to the CFHR3 SNP that is outside of the deleted region. The authors should clarify to readers the exact understanding of the relationship between *N. meningitidis* risk and the CFHR3/CFHR1 deletion. If that connection is not established through population studies then what could be the proposed mechanistic link to the CFHR3 polymorphism(s)?

2\) In contrast to the binding assays, the actual differences in relative survival of *N. meningitidis* in the presence and absence of CFHR3 are rather modest ([Figure 3d, e, 4c](#fig3 fig4){ref-type="fig"}). In addition, only one serum concentration and one protein concentration is used. In what is likely to be optimized conditions, the differences are \<two-fold. Given the non-linear activities of the complement alternative pathway (AP) and amplification loop, it is not certain how modest changes in serum concentration would impact the results with different CFHR3/CFH ratios. To address this issue, the authors should present results of killing assays using a range of serum and protein concentrations. The authors should also include the fHbp-deficient *N. meningitidis* mutant strain as well as complementation by E255A as controls. Moreover, statistics should be also performed on the differences between normal human serum (NHS) and heat-inactivated serum with different CFHR3 proteins with p values calculated.

3\) Serum killing assays are of course only an approximation of the complex bacterial protective response in vivo. Although there are no good animal models of human CFHR activities, inclusion of human neutrophils can provide a more complete analysis of the relationship between serum complement-bactericidal activity and bacterial killing (see for instance Ross et al, J Infect Dis. (1987) 155 (6): 1266-1275). The authors should perform such combined serum- and cell-based assays in which a more complete role of complement, and in particular its C3 fragment receptors on neutrophils, can be evaluated for their contribution to bacterial killing.

4\) CFH and CFHR3 are generally considered to have similar function of negatively regulating the complement activity. However, the authors indicate here and in previous studies that this perception is wrong and CFHR3 can compete with CFH to bind the C3b complex and therefore counteract the negative function of CFH. The authors should go beyond the erythrocyte haemolysis assay in [Figure 1b](#fig1){ref-type="fig"} and examine the general function of CFHR3 in serum-mediating killing of bacteria that have nothing to do with CFH/CFHR3 binding (also consider using their CFHR3-deficient sera). This is particularly important in that pathogens exhibit a wide variety of mechanisms to evade the in vivo immune response, most of which do not directly target the complement system. In that context, additional support for an important role by this mechanism would add substantially to the relevance and potential impact of the study.

5\) According to the authors\' model, the function of CFHR3 should depend on the presence of CFH. However, there were no direct evidences demonstrating this point. Can CFH-deficient serum be found? If not, is it possible to deplete or block CFH by using CFH-specific antibody? In the latter, the authors can then examine whether exogenous CFHR3 still has any effect on complement-mediated killing in the sera in the absence of CFH function.
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Author response

1\) As a rationale for the study and also a clinically relevant conclusion, the authors point to a recent GWAS study showing linkage disequilibrium to a specific SNP and hence indicating the possibility that the linkage could be a result of deletion of CFHR3/CFHR1. In reading the Nature Genetics report, though, it does not appear that the CFHR3/CFHR1 deletion itself is linked to disease risk, but the association is rather to the CFHR3 SNP that is outside of the deleted region. The authors should clarify to readers the exact understanding of the relationship between N. meningitidis risk and the CFHR3/CFHR1 deletion. If that connection is not established through population studies, then what could be the proposed mechanistic link to the CFHR3 polymorphism(s)?

The GWAS study by Davila *et al.* did not show an association with the CFHR3‐1 deletion polymorphism as evident by the lack of an association between macular degeneration and the typed rs6677604 SNP (Davila et al., Nature Genetics 2010, Supplemental data Table 3). This SNP tags the CFHR3--1 deletion in many populations. The statistically significant associations in the GWAS study consisted of SNPs within CFH, within CFHR3 and within CFHR1, although the latter failed genotyping in one of the cohorts \[Spanish\] so was not included in the combined analysis (Davila et al., Nature Genetics 2010, Table 2). On the data presented it was not possible to conclude that the identified SNPs were causal because many of them were in linkage disequilibrium across the CFH--CFHR locus. In fact Davila et al. make the point "these CFH and CFHR SNPs are statistically indistinguishable from one another, and further work, such as deep resequencing, may be needed to identify the causal variant or variants within the associated region if the currently identified SNPs are not the functional variants". What we can robustly conclude from the existing data is that variation within the CFH--CFHR locus influences susceptibility to macular degeneration. This includes variation within CFH (not unexpected from observations from complement deficiency states) and within the CFHR protein family (unexpected). Our functional studies support an association with variation within CFHR3. We have modified the text to reflect these comments.

*2) In contrast to the binding assays, the actual differences in relative survival of N. meningitidis in the presence and absence of CFHR3 are rather modest (*[*Figure 3d, e, 4c*](#fig3 fig4){ref-type="fig"}*)*.

The difference in survival on the addition of CFHR3 is approximately 40% in the assay we performed that was over the course of 30 minutes. Although the difference appears modest to the reviewer, this will be marked during bacteraemia over hours in an infected individual. For example, over two hours the presence of CFHR3 would result in 88% less in survival of bacteria in the presence of CRHR3 compared to an individual with ΔCFHR3‐CFHR1 (and a 95% difference over 3 hrs).

*In addition, only one serum concentration and one protein concentration is used. In what is likely to be optimized conditions, the differences are \<two-fold. Given the non-linear activities of the AP and amplification loop, it is not certain how modest changes in serum concentration would impact the results with different CFHR3/CFH ratios. To address this issue, the authors should present results of killing assays using a range of serum and protein concentrations. The authors should also include the fHbp-deficient N. meningitidis mutant strain as well as complementation by E255A as controls*.

As suggested by the reviewers, we have evaluated the effect of the different concentrations of CFHR3 on the survival of wild‐type bacteria and the isogenic fHbp mutant. The amount of serum in both the NHS and AP assays was kept constant to give approximately 80% bacterial survival without additional CFHR3; this enables the impact of this de‐regulator (which was expected to decrease survival) to be determined. The results demonstrate that the effect of CFHR3 (Mol Microbiol. 2011 Sep;81(5):1330-42; Nat Rev Microbiol. 2012 Jan 31;10(3):178-90) on meningococcal survival is dose and fHbp dependent ([Figure 1](#fig1){ref-type="fig"}). We now include these results as supplementary data ([Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}, panel a).

*Moreover, statistics should be also performed on the differences between NHS and heat inactivated serum with different CFHR3 proteins with p values calculated*.

We have added the relevant statistical analyses to the Figure ([Figure 3D](#fig3){ref-type="fig"} in our revised manuscript) as requested.

*3) Serum killing assays are of course only an approximation of the complex bacterial protective response in vivo. Although there are no good animal models of human CFHR activities, inclusion of human neutrophils can provide a more complete analysis of the relationship between serum complement-bactericidal activity and bacterial killing (see for instance Ross et al, J Infect Dis. (1987) 155 (6): 1266-1275). The authors should perform such combined serum- and cell-based assays in which a more complete role of complement and in particular its C3 fragment receptors on neutrophils can be evaluated for their contribution to bacterial killing*.

This is an interesting suggestion. Marked susceptibility to meningococcal disease is seen in individuals with rare complement defects (especially loss of components of the terminal pathway, which is necessary for bacteriolysis and not opsonphagocytosis), those receiving C5 inhibitors (i.e. eculizumab), and inherited defects of the AP (i.e. properdin and factor D deficiencies). Furthermore, the established correlate of protection against meningococcal disease is the presence in the serum of bactericidal antibodies (i.e. antibodies that trigger the classical complement pathway and cause bacteriolysis).

In contrast, neutropaenic patients and people unable to generate a neutrophil anti-microbial oxidative burst do not exhibit high rates of meningococcal disease. This is consistent with the detection of diplococci in neutrophils in the cerebrospinal fluid and blood of patients with meningococcal disease (the bacterium was originally named *Diplococcus intracellulare*) and the resistance of pathogenic Neisseria to killing by neutrophils in the laboratory (shown by us and others, e.g., Mol Microbiol. 2011 Sep;81(5):1330-42; Nat Rev Microbiol. 2012 Jan 31;10(3):178-90). Work cited by the reviewer used a large number of uncharacterised bacterial strains and no details were provided about the method of recovery of neutrophils (which affects their activation status/NET formation).

Therefore neither genetic, clinical nor laboratory evidence implicates polymorphonuclear leukocytes and opsonphagocytosis in innate immunity against the meningococcus. Therefore work with polymorphonuclear leukocytes would not contribute any further insights into the effects of CFHRs. However, in line with the reviewers' comments, we now discuss this point in the manuscript.

*4) CFH and CFHR3 are generally considered to have similar function of negatively regulating the complement activity. However, the authors indicate here and in previous studies that this perception is wrong and CFHR3 can compete with CFH to bind to C3b complex and therefore counteract the negative function of CFH. The authors should go beyond the erythrocyte haemolysis assay in* [*Figure 1b*](#fig1){ref-type="fig"} *and examine the general function of CFHR3 in serum-mediating killing of bacteria that have nothing to do with CFH/CFHR3 binding (also consider using their CFHR3-deficient sera). This is particularly important in that pathogens exhibit a wide variety of mechanisms to evade the in vivo immune response, most of which do not directly target the complement system. In that context, additional support for an important role by this mechanism would add substantially to the relevance and potential impact of the study*.

Our hypothesis, supported by the data in [Figure 1](#fig1){ref-type="fig"}, is that CFHR3 has no activity except in its ability to compete for the same binding sites as CFH. This is now further supported by the additional demonstration that CFHR3 *per se* has no effect on complement-mediated lysis in the absence of CFH (see [Figure 1--figure supplement 1](#fig1s1){ref-type="fig"} and the answer to point 5 below). As suggested by the reviewer, to further exemplify this point we have now examined serum-mediated killing of *E. coli* since these do not express any CFH binding protein. These new data (now incorporated into [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}, panel b) clearly demonstrate that addition of CFHR3 has no direct effect on killing of this bacterium.

*5) According to the authors\' model, the function of CFHR3 should depend on the presence of CFH. However, there were no direct evidences demonstrating this point. Can CFH-deficient serum be found? If not, is it possible to deplete or block CFH by using CFH-specific antibody? In the latter, the authors can then examine whether exogenous CFHR3 still has any effect on complement-mediated killing in the sera in the absence of CFH function*.

Working with CFH-deficient sera is difficult as it is prone to full complement activation following relatively minor insult. However, as suggested, we have now repeated the haemolytic assays in CFH-deficient sera and show that addition of CFHR3 has no effect on haemolysis in the absence of CFH (new [Figure 1--figure supplement 1](#fig1s1){ref-type="fig"}). Furthermore, reconstitution of the sera with CFH restores the ability of CFHR3 to promote haemolysis.

[^1]: These authors contributed equally to this work.
